- Trials with a EudraCT protocol (5,634)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
5,634 result(s) found for: Blood serum.
Displaying page 1 of 282.
EudraCT Number: 2016-002583-14 | Sponsor Protocol Number: CICL670A2201 | Start Date*: 2016-11-25 |
Sponsor Name:Novartis Pharmaceuticals Corp | ||
Full Title: A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients... | ||
Medical condition: Sickle Cell Disease/ Iron Overload | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-005355-32 | Sponsor Protocol Number: IIV-275 | Start Date*: 2014-03-06 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003943-55 | Sponsor Protocol Number: MDS0706 | Start Date*: 2007-09-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs) | |||||||||||||
Medical condition: Adlut patients with low risk MDS (IPPS 0-1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000995-88 | Sponsor Protocol Number: V00305SB301 | Start Date*: 2016-04-12 |
Sponsor Name:Pierre Fabre Médicament | ||
Full Title: Study of efficacy and safety of V0305 solution in children suffering from Iron Deficiency Anaemia (IDA). Phase 3, multicentre, single arm open-label study | ||
Medical condition: Iron Deficiency Anaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000501-22 | Sponsor Protocol Number: SPON1189-13 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Cardiff Univeristy | |||||||||||||
Full Title: A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combinin... | |||||||||||||
Medical condition: Acute Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001252-41 | Sponsor Protocol Number: NA | Start Date*: 2022-07-08 |
Sponsor Name:CHU de Liège | ||
Full Title: Preventing postoperative anaemia in total knee arthroplasty and impact of intravenous iron supplementation on postoperative functional recovery : a randomized clinical trial | ||
Medical condition: Total Knee Arthroplasty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003619-23 | Sponsor Protocol Number: 6630-4200-42 | Start Date*: 2019-11-29 |
Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG | ||
Full Title: EFFICACY AND SAFETY OF A PARENTERALLY ADMINISTERED FIXED VITAMIN COMBINATION (VITAMIN B6, B12 AND FOLIC ACID) ON VITAMIN B12 STATUS AND METHYLATION CAPACITY IN COBALAMIN DEFICIENCY COMPARED TO ORAL... | ||
Medical condition: vitamin B12 deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004212-21 | Sponsor Protocol Number: AMAG-423-201 | Start Date*: 2019-05-24 | |||||||||||
Sponsor Name:AMAG Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree... | |||||||||||||
Medical condition: Severe Preeclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003567-31 | Sponsor Protocol Number: KPUK0106 | Start Date*: 2007-05-25 | ||||||||||||||||
Sponsor Name:Med. Klinik II, Grosshadern, Klinikum der Universität München | ||||||||||||||||||
Full Title: Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients | ||||||||||||||||||
Medical condition: hypertension metabolic syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004813-15 | Sponsor Protocol Number: VERSPLASMA | Start Date*: 2021-03-19 |
Sponsor Name:AZ Turnhout | ||
Full Title: Serum concentrations of ropivacaine after unilateral pectoral nerve block type II (Pecs II) in breast cancer surgery | ||
Medical condition: The aim of this study is to quantify peak and mean venous serum concentrations of ropivacaine after ultrasound guided Pecs II block with 2.5mg/kg ropivacaine diluted to 30ml. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015982-29 | Sponsor Protocol Number: UMCU-Vasc-14A | Start Date*: 2010-07-27 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||||||||||||
Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyper... | ||||||||||||||||||||||||||||
Medical condition: Hypertension in subjects with abdominal obesity and the metabolic syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003776-13 | Sponsor Protocol Number: ALN-AGT01-003 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled b... | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001786-26 | Sponsor Protocol Number: 3004 | Start Date*: 2014-07-02 | |||||||||||
Sponsor Name:Steno Diabetes Center | |||||||||||||
Full Title: A randomised, doublet blinded, placebo controlled cross-over study of Allopurinols effect to prevent loss of kidney function in type 1 diabetes | |||||||||||||
Medical condition: Type 1 diabetes and microalbuminuria. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007516-28 | Sponsor Protocol Number: CYT006-AngQb 03 | Start Date*: 2008-06-06 | |||||||||||
Sponsor Name:Cytos Biotechnology AG | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vac... | |||||||||||||
Medical condition: Mild to moderate essential hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000275-36 | Sponsor Protocol Number: CSUB0202 | Start Date*: 2021-04-23 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: Prevention of Glucocorticoid induced impairment of bone metabolism – A Randomized, Placebo-Controlled, Single Centre Clinical Trial | ||
Medical condition: Oral glucocorticoid (GC) therapy leads to a rapid and profound effects on bone metabolism.The gut microbiota is involved in regulating bone metabolism.Lactobacillus reuteri (LR) has been shown to h... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000967-42 | Sponsor Protocol Number: IIV-276 | Start Date*: 2014-05-20 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM) | ||
Full Title: Strengthening memory immunity in the aged population by vaccinating re-elderly | ||
Medical condition: The vaccine administered in this study is used to prevent meningococcal disease caused by the bacteria Neisseria meningitidis group A,C,W,Y (Nimenrix) and Herpes Zoster disease caused by the Vari... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004825-26 | Sponsor Protocol Number: G200712 | Start Date*: 2013-01-25 | ||||||||||||||||
Sponsor Name:GTx, Inc. | ||||||||||||||||||
Full Title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on and... | ||||||||||||||||||
Medical condition: Assessments of serum total testosterone, serum free testosterone, serum SHGB and serum PSA concentrations will be made. Bone turnover markers and the incidence and frequency of hot flashes will be ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005843-93 | Sponsor Protocol Number: CYT006-AngQb 02 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:Cytos Biotechnology AG | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccin... | |||||||||||||
Medical condition: Mild to moderate essential hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005925-31 | Sponsor Protocol Number: LAC02 | Start Date*: 2008-01-31 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF 6-MONTH ACETYLCARNITINE THERAPY ON ARTERIAL BLOOD PRESSURE, LIPID AND METABOLIC PROFILE, AND KIDNEY FUNCT... | |||||||||||||
Medical condition: Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004414-10 | Sponsor Protocol Number: TERIFL08519 | Start Date*: 2018-02-23 |
Sponsor Name:MS Centrum, Department of Neurology, Sshlgrenska University Hospital | ||
Full Title: Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily. | ||
Medical condition: Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
